HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
THC
Tenet Healthcare Corporation
THC's fundamentals are strong and it looks cheap: trading at 8.3x earnings, below its usual 11x. Analysts expect earnings growth, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
THC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Healthy |
THC's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
THC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6x | $207 | -28% |
| Current | 8.3x | $287 | — |
| Fair | 11x | $365 | +27% |
| Forward | 14x | $287 | — |
| Expensive | 17x | $590 | +106% |
Historical ranges are pointers, not guarantees.
THC's PE is in its cheap range at 8.3x. On analysts' estimates for next year's earnings, today's price would be 14x, in its expensive range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
THC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect THC's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
THC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $20.30 | -41% |
| Q3 2026 | $34.48 | +129% |
| Q2 2026 | $25.93 | +61% |
| Q1 2026 | $19.23 | +23% |
| Q4 2025 | $15.49 | -53% |
| Q3 2025 | $15.06 | -52% |
| Q2 2025 | $16.09 | -41% |
| Q1 2025 | $15.59 | -40% |
| Q4 2024 | $32.70 | +473% |
THC has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over THC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
THC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.6B | +6.5% |
| Q2 2026 | $5.6B | +6.8% |
| Q1 2026 | $5.4B | +2.8% |
| Q4 2025 | $5.5B | +9% |
| Q3 2025 | $5.3B | +3.3% |
| Q2 2025 | $5.3B | +3.3% |
| Q1 2025 | $5.2B | -2.7% |
| Q4 2024 | $5.1B | -5.7% |
THC's revenue has grown year over year for six quarters in a row: $5.6B last quarter, up 6.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 31% | +14 points |
| Q2 2026 | 27% | +11 points |
| Q1 2026 | 24% | +6.1 points |
| Q4 2025 | 15% | -0.8 points |
| Q3 2025 | 17% | -4.5 points |
| Q2 2025 | 16% | +0.7 points |
| Q1 2025 | 18% | -43 points |
| Q4 2024 | 16% | +2.5 points |
THC has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over THC on cash flow, with more consistent year-over-year improvement.
THC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +39% |
| Q2 2026 | $417M | -44% |
| Q1 2026 | $1.5B | +128% |
| Q4 2025 | $367M | +$1B |
| Q3 2025 | $778M | -6.2% |
| Q2 2025 | $743M | +23% |
| Q1 2025 | $642M | +86% |
| Q4 2024 | -$661M | -207% |
THC generated $3.3B in free cash flow over the past year, up 122% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
THC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4% | -3.4M shares |
| 1 year | -9% | -8M shares |
| 3 years | -23% | -23.8M shares |
| 5 years | -26% | -28.2M shares |
| Available history | -22% | -22.8M shares |
THC has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $255M |
| Q2 2026 | $1B |
| Q1 2026 | $318M |
| Q4 2025 | $198M |
| Q3 2025 | $93M |
| Q2 2025 | $747M |
| Q1 2025 | $348M |
| Q4 2024 | — |
THC spent $1.8B buying back its own shares over the past year, up 53% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
THC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 2.0x | Moderate |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.4x | Moderate |
| Q3 2025 | 2.4x | Moderate |
| Q2 2025 | 2.4x | Moderate |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 1.5x | Healthy |
THC's net debt is about 1.7 years of its operating earnings (EBITDA), down from 2.4 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
THC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.8 | Overbought |
| Stochastic | 73.5 | Neutral |
THC's weekly RSI is 72 (overbought) and its Stochastic is 73 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
THC PE vs Healthcare Sector
| Metric | THC | Sector median | Relative |
|---|---|---|---|
| PE | 8.3x | 26x | 68% below |
| PE % | 32 | 29 | 3 pts above |
THC is trading at 8.3x earnings, a 68% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
THC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $270.2 | 6.2% above |
| 20 week MA | $256.0 | 12% above |
| 50 week MA | $220.8 | 30% above |
| 100 week MA | $190.8 | 50% above |
| 200 week MA | $144.1 | 99% above |
THC has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
THC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $38.3 | $40.1 | +4.9% |
| 2021 | $40.1 | $79.3 | +98% |
| 2022 | $79.3 | $46.6 | -41% |
| 2023 | $46.6 | $75.6 | +62% |
| 2024 | $75.6 | $128.0 | +69% |
| 2025 | $128.0 | $200.6 | +57% |
| 2026 YTD | $200.6 | $286.9 | +43% |
THC has the edge over HIMS on returns for 2026, with the stronger performance.